SiRNA-mediated allele-specific silencing of a COL6A3 mutation in a cellular model of dominant ullrich muscular dystrophy

Molecular Therapy Nucleic Acids

Volumn 3, Issue , 2014, Pages

  Bolduc, Véronique ^a   Zou, Yaqun ^a   Ko, Dayoung ^a   Bönnemann, Carsten G ^a  

^a NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE; COLLAGEN TYPE 6; RNA INDUCED SILENCING COMPLEX; SMALL INTERFERING RNA; COLLAGEN 6 A3; MESSENGER RNA; UNCLASSIFIED DRUG;

ALLELE; ANTISENSE THERAPY; ARTICLE; CASE REPORT; CONFOCAL MICROSCOPY; CONGENITAL MUSCULAR DYSTROPHY TYPE ULLRICH; CONTROLLED STUDY; ENDOPLASMIC RETICULUM STRESS; EXON; EXTRACELLULAR MATRIX; FIBROBLAST; GENE AMPLIFICATION; GENE CONSTRUCT; GENE SILENCING; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; MUSCULAR DYSTROPHY; MUTATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; REPORTER GENE; RNA INTERFERENCE; UNFOLDED PROTEIN RESPONSE; ALTERNATIVE RNA SPLICING; COLLAGEN SYNTHESIS; DOMINANT ULLRICH MUSCULAR DYSTROPHY; GENE MUTATION; GENE TARGETING; IMMUNOBLOTTING; IMMUNOFLUORESCENCE; QUANTITATIVE ANALYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

EID: 84894128585     PISSN: None     EISSN: 21622531     Source Type: Journal    
DOI: 10.1038/mtna.2013.74     Document Type: Article

References (42)

1. Camacho Vanegas, O, Bertini, E, Zhang, RZ, Petrini, S, Minosse, C, Sabatelli, P et al. (2001). Ullrich scleroatonic muscular dystrophy is caused by recessive mutations in collagen type VI. Proc Natl Acad Sci USA 98:7516-7521 (Pubitemid 32567980)
2. Demir, E, Sabatelli, P, Allamand, V, Ferreiro, A, Moghadaszadeh, B, Makrelouf, M et al. (2002). Mutations in COL6A3 cause severe and mild phenotypes of Ullrich congenital muscular dystrophy. Am J Hum Genet 70:1446-1458. (Pubitemid 34533892)
3. Pan, TC, Zhang, RZ, Sudano, DG, Marie, SK, Bönnemann, CG and Chu, ML (2003). New molecular mechanism for Ullrich congenital muscular dystrophy: a heterozygous in-frame deletion in the COL6A1 gene causes a severe phenotype. Am J Hum Genet 73:355-369. (Pubitemid 36920997)
4. Bönnemann, CG (2011). The collagen VI-related myopathies: muscle meets its matrix. Nat Rev Neurol 7:379-390.
5. Nadeau, A, Kinali, M, Main, M, Jimenez-Mallebrera, C, Aloysius, A, Clement, E et al. (2009). Natural history of Ullrich congenital muscular dystrophy. Neurology 73:25-31.
6. Engel, J, Furthmayr, H, Odermatt, E, Von Der Mark, H, Aumailley, M, Fleischmajer, R et al. (1985). Structure and macromolecular organization of type VI collagen. Ann N Y Acad Sci 460:25-37. (Pubitemid 16074807)
7. Chu, ML, Pan, TC, Conway, D, Saitta, B, Stokes, D, Kuo, HJ et al. (1990). The structure of type VI collagen. Ann N Y Acad Sci 580:55-63. (Pubitemid 20170386)
8. Weil, D, Mattei, MG, Passage, E, N'Guyen, VC, Pribula-Conway, D, Mann, K et al. (1988). Cloning and chromosomal localization of human genes encoding the three chains of type VI collagen. Am J Hum Genet 42:435-445.
9. Chu, ML, Conway, D, Pan, TC, Baldwin, C, Mann, K, Deutzmann, R et al. (1988). Amino acid sequence of the triple-helical domain of human collagen type VI. J Biol Chem 263:18601-18606. (Pubitemid 19016317)
10. Engvall, E, Hessle, H and Klier, G (1986). Molecular assembly, secretion, and matrix deposition of type VI collagen. J Cell Biol 102:703-710. (Pubitemid 16013128)
11. Furthmayr, H, Wiedemann, H, Timpl, R, Odermatt, E and Engel, J (1983). Electronmicroscopical approach to a structural model of intima collagen. Biochem J 211:303-311. (Pubitemid 13092520)
12. Colombatti, A, Mucignat, MT and Bonaldo, P (1995). Secretion and matrix assembly of recombinant type VI collagen. J Biol Chem 270:13105-13111.
13. Lamandé, SR, Sigalas, E, Pan, TC, Chu, ML, Dziadek, M, Timpl, R et al. (1998). The role of the alpha3 (VI) chain in collagen VI assembly. Expression of an alpha3 (VI) chain lacking N-terminal modules N10-N7 restores collagen VI assembly, secretion, and matrix deposition in an alpha3 (VI)-defcient cell line. J Biol Chem 273:7423-7430. (Pubitemid 28152764)
14. Baker, NL, Mörgelin, M, Peat, R, Goemans, N, North, KN, Bateman, JF et al. (2005). Dominant collagen VI mutations are a common cause of Ullrich congenital muscular dystrophy. Hum Mol Genet 14:279-293.
15. Lampe, AK, Zou, Y, Sudano, D, O'Brien, KK, Hicks, D, Laval, SH et al. (2008). Exon skipping mutations in collagen VI are common and are predictive for severity and inheritance. Hum Mutat 29:809-822. (Pubitemid 351794132)
16. Allamand, V, Briñas, L, Richard, P, Stojkovic, T, Quijano-Roy, S and Bonne, G (2011). ColVI myopathies: where do we stand, where do we go? Skelet Muscle 1:30.
17. Peat, RA, Smith, JM, Compton, AG, Baker, NL, Pace, RA, Burkin, DJ et al. (2008). Diagnosis and etiology of congenital muscular dystrophy. Neurology 71:312-321.
18. Briñas, L, Richard, P, Quijano-Roy, S, Gartioux, C, Ledeuil, C, Lacène, E et al. (2010). Early onset collagen VI myopathies: Genetic and clinical correlations. Ann Neurol 68:511-520.
19. Pan, TC, Zhang, RZ, Pericak-Vance, MA, Tandan, R, Fries, T, Stajich, JM et al. (1998). Missense mutation in a von Willebrand factor type A domain of the alpha 3 (VI) collagen gene (COL6A3) in a family with Bethlem myopathy. Hum Mol Genet 7:807-812. (Pubitemid 28221243)
20. Jöbsis, GJ, Keizers, H, Vreijling, J P, De Visser, M, Speer, MC, Wolterman, RA et al. (1996). Type VI collagen mutations in Bethlem myopathy, an autosomal dominant myopathy with contractures. Nat Genet 14:113-115. (Pubitemid 26301559)
21. Pepe, G, Giusti, B, Bertini, E, Brunelli, T, Saitta, B, Comeglio, P et al. (1999). A heterozygous splice site mutation in COL6A1 leading to an in-frame deletion of the alpha1 (VI) collagen chain in an italian family affected by bethlem myopathy. Biochem Biophys Res Commun 258:802-807. (Pubitemid 29290351)
22. Hicks, D, Lampe, AK, Barresi, R, Charlton, R, Fiorillo, C, Bonnemann, CG et al. (2008). A refned diagnostic algorithm for Bethlem myopathy. Neurology 70:1192-1199. (Pubitemid 351482571)
23. Ishikawa, H, Sugie, K, Murayama, K, Awaya, A, Suzuki, Y, Noguchi, S et al. (2004). Ullrich disease due to defciency of collagen VI in the sarcolemma. Neurology 62:620-623. (Pubitemid 38252806)
24. Foley, AR, Hu, Y, Zou, Y, Yang, M, Medne, L, Leach, M et al. (2011). Large genomic deletions: a novel cause of Ullrich congenital muscular dystrophy. Ann Neurol 69:206-211.
25. Elbashir, SM, Harborth, J, Lendeckel, W, Yalcin, A, Weber, K and Tuschl, T (2001). Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. Nature 411:494-498. (Pubitemid 32494397)
26. Burnett, JC and Rossi, JJ (2012). RNA-based therapeutics: current progress and future prospects. Chem Biol 19:60-71.
27. Schwarz, DS, Hutvágner, G, Du, T, Xu, Z, Aronin, N and Zamore, PD (2003). Asymmetry in the assembly of the RNAi enzyme complex. Cell 115:199-208. (Pubitemid 37329583)
28. Zou, Y, Zhang, RZ, Sabatelli, P, Chu, ML and Bönnemann, CG (2008). Muscle interstitial fbroblasts are the main source of collagen VI synthesis in skeletal muscle: implications for congenital muscular dystrophy types Ullrich and Bethlem. J Neuropathol Exp Neurol 67:144-154.
29. Carthew, RW and Sontheimer, EJ (2009). Origins and Mechanisms of miRNAs and siRNAs. Cell 136:642-655.
30. Jimenez-Mallebrera, C, Maioli, MA, Kim, J, Brown, SC, Feng, L, Lampe, AK et al. (2006). A comparative analysis of collagen VI production in muscle, skin and fbroblasts from 14 Ullrich congenital muscular dystrophy patients with dominant and recessive COL6A mutations. Neuromuscul Disord 16:571-582. (Pubitemid 44374327)
31. Kern, P, Menasche, M and Robert, L (1991). Relative rates of biosynthesis of collagen type I, type V and type VI in calf cornea. Biochem J 274(Pt 2):615-617.
32. Sabatelli, P, Bonaldo, P, Lattanzi, G, Braghetta, P, Bergamin, N, Capanni, C et al. (2001). Collagen VI defciency affects the organization of fbronectin in the extracellular matrix of cultured fbroblasts. Matrix Biol 20:475-486. (Pubitemid 33016384)
33. Butterfeld, RJ, Foley, AR, Dastgir, J, Asman, S, Dunn, DM, Zou, Y et al. (2013). Position of glycine substitutions in the triple helix of COL6A1, COL6A2, and COL6A3 is correlated with severity and mode of inheritance in collagen VI myopathies. Hum Mutat 34:1558-1567.
34. Norwood, FL, Harling, C, Chinnery, P F, Eagle, M, Bushby, K and Straub, V (2009). Prevalence of genetic muscle disease in Northern England: in-depth analysis of a muscle clinic population. Brain 132(Pt 11):3175-3186.
35. Clement, EM, Feng, L, Mein, R, Sewry, CA, Robb, SA, Manzur, AY et al. (2012). Relative frequency of congenital muscular dystrophy subtypes: analysis of the UK diagnostic service 2001-2008. Neuromuscul Disord 22:522-527.
36. Kawahara, G, Ogawa, M, Okada, M, Malicdan, MC, Goto, Y, Hayashi, YK et al. (2008). Diminished binding of mutated collagen VI to the extracellular matrix surrounding myocytes. Muscle Nerve 38:1192-1195.
37. Gualandi, F, Manzati, E, Sabatelli, P, Passarelli, C, Bovolenta, M, Pellegrini, C et al. (2012). Antisense-induced messenger depletion corrects a COL6A2 dominant mutation in Ullrich myopathy. Hum Gene Ther 23:1313-1318.
38. Pendaries, V, Gasc, G, Titeux, M, Tonasso, L, Mejía, JE and Hovnanian, A (2012). siRNA-mediated allele-specifc inhibition of mutant type VII collagen in dominant dystrophic epidermolysis bullosa. J Invest Dermatol 132:1741-1743.
39. Lindahl, K, Rubin, CJ, Kindmark, A and Ljunggren, O (2008). Allele dependent silencing of COL1A2 using small interfering RNAs. Int J Med Sci 5:361-365.
40. Müller, GA, Hansen, U, Xu, Z, Griswold, B, Talan, MI, McDonnell, NB et al. (2012). Allelespecifc siRNA knockdown as a personalized treatment strategy for vascular Ehlers-Danlos syndrome in human fbroblasts. FASEB J 26:668-677.
41. Rettig, GR and Behlke, MA (2012). Progress toward in vivo use of siRNAs-II. Mol Ther 20:483-512.
42. Deleavey, GF and Damha, MJ (2012). Designing chemically modifed oligonucleotides for targeted gene silencing. Chem Biol 19:937-954.